Updates are available Correction dated 2019-01-04

Click to view Correction: https://doi.org/10.1007/s40267-018-00596-3

Correction to: “Correction to: Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use”

Crossref DOI link: https://doi.org/10.1007/s40267-019-00613-z

Published Online: 2019-02-21

Published Print: 2019-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark